Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Pharmicell Co's share price for the quarter that ended in Mar. 2024 was ₩6250. Pharmicell Co's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 60 Mil. Therefore, Pharmicell Co's market cap for the quarter that ended in Mar. 2024 was ₩375,025 Mil.
Pharmicell Co's quarterly market cap
declined
from Sep. 2023 (₩433,229 Mil) to Dec. 2023 (₩364,224 Mil) but then
increased
from Dec. 2023 (₩364,224 Mil) to Mar. 2024 (₩375,025 Mil).
Pharmicell Co's annual market cap
declined
from Dec. 2021 (₩782,295 Mil) to Dec. 2022 (₩678,045 Mil) and
declined
from Dec. 2022 (₩678,045 Mil) to Dec. 2023 (₩364,224 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pharmicell Co's Enterprise Value for Today is ₩351,213 Mil.
Pharmicell Co Market Cap Historical Data
The historical data trend for Pharmicell Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pharmicell Co's Market Cap
For the Biotechnology subindustry, Pharmicell Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmicell Co's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmicell Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Pharmicell Co's Market Cap falls into.
Pharmicell Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Pharmicell Co's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmicell Co (XKRX:005690) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Pharmicell Co Market Cap Related Terms
Thank you for viewing the detailed overview of Pharmicell Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:005690 has been successfully added to your 